Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ErbB3 siRNA
- Development stage
- Preclinical
- Lead developer
- Cell Signaling Technology
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Intravenous, Intratumoral
01
Overview
ErbB3 siRNA is a research-stage RNA interference (RNAi) modality designed to selectively silence the expression of the ErbB3 (HER3) receptor. ErbB3 is a member of the epidermal growth factor receptor (EGFR) family that, while lacking intrinsic kinase activity, plays a critical role in oncogenic signaling by heterodimerizing with other family members like ErbB2 (HER2) or EGFR. By targeting ErbB3 mRNA for degradation via the RNA-induced silencing complex (RISC), this siRNA inhibits the translation of the receptor, thereby disrupting downstream PI3K/AKT signaling pathways essential for tumor cell survival, proliferation, and motility. It has been investigated in various preclinical models, including lung adenocarcinoma, cutaneous melanoma, and cervical cancer, demonstrating significant tumor growth inhibition in xenograft mouse models.
- Brand names
- SignalSilence HER3/ErbB3 siRNA
- Other names
- HER3 siRNAHER-3 siRNAHER 3 siRNAErbB3 small interfering RNAErbB-3 small interfering RNAErbB 3 small interfering RNA
02
Targets
ERBB3 (Erb-b2 receptor tyrosine kinase 3)
Beyond the preview
Go deeper on ErbB3 siRNA.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ErbB3 siRNA.